

—Original—

Th2-biased GATA-3 transgenic mice developed severe experimental peritoneal fibrosis compared with Th1-biased T-bet and Th17-biased RORyt transgenic mice

Keigyou YOH¹⁾, Masami OJIMA¹⁾, and Satoru TAKAHASHI^{1–4)}

¹⁾Anatomy and Embryology, Division of Biomedical Science, Faculty of Medicine, University of Tsukuba, Japan

²⁾International Institute for Integrative Sleep Medicine (WPI-IIIS), Faculty of Medicine, University of Tsukuba, Japan

³⁾Life Science Center, Tsukuba Advanced Research Alliance (TARA), Faculty of Medicine, University of Tsukuba, Japan

⁴⁾Laboratory Animal Resource Center (LARC), Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan

Abstract: Encapsulating peritoneal sclerosis is one of the most serious complications of long-term peritoneal dialysis. The pathogenesis of encapsulating peritoneal sclerosis has not been elucidated, but several putative factors necessary for the development of peritoneum fibrosis (PF) have been reported. However, the roles of T helper (Th) cells in the progression of PF are unknown. The purpose of this study was to clarify the roles of Th1, Th2, and Th17 cells in the progression of PF. T-bet, GATA-3, and RORyt are Th1, Th2, and Th17 lineage commitment transcription factors, respectively. We previously generated Th1-biased (T-bet transgenic (Tg)) mice, Th2-biased (GATA-3 Tg) mice, and Th17-biased (RORyt Tg) mice. In this study, Th1, Th2, Th17-biased, and wild-type mice were administered chlorhexidine gluconate (CG) intraperitoneally and analyzed on day 21. CG-injected GATA-3 Tg mice showed a distended intestinal tract and developed marked thickening of the submesothelial space compared with the other groups. CG-injected GATA-3 Tg mice also showed significant expression of α -SMA positive cells, macrophages, and collagen III in the submesothelium. In contrast, CG-injected T-bet Tg mice only developed mild peritoneal fibrosis. Cytokines analysis in peritoneal fluid showed that IFN- γ was significantly increased in CG-injected T-bet Tg mice and that IL-13 was significantly increased in CG-injected GATA-3 Tg mice. Moreover, intraperitoneal administration of IFN- γ improved PF in CG-injected wild-type mice. Our results suggest that Th2 cells may play roles in the development of experimental PF and that Th1 cells may alleviate the severity of experimental PF.

Key words: IFN- γ , peritoneal fibrosis, T helper cell type 1, T helper cell type 2

Introduction

Encapsulating peritoneal sclerosis (EPS) is a severe complication of long-term peritoneal dialysis (PD). EPS is characterized by progressive and excessive fibrotic

thickening of the peritoneum, leading to encapsulation of the bowels and intestinal obstruction [18]. Several reports have shown an increase in the incidence of EPS, especially in long-term PD patients [3, 12, 13]. Kawanishi *et al.* reported an overall incidence of 2.5%, with

(Received 12 March 2015 / Accepted 10 April 2015 / Published online in J-STAGE 9 July 2015)

Address corresponding: K. Yoh, Anatomy and Embryology, Division of Biomedical Science, Faculty of Medicine, University of Tsukuba, 1-1-1 Ten-nodai, Tsukuba, Ibaraki 305-8575, Japan

Supplementary figures: refer to J-STAGE: <https://www.jstage.jst.go.jp/browse/expanim>

©2015 Japanese Association for Laboratory Animal Science

a higher incidence of 17.2% and a mortality rate of 100% for patients suffering from PD for more than 15 years [13]. A recent study by Johnson *et al.* showed that the respective cumulative incidences of peritoneal sclerosis at 5, and 8 years were 0.8, and 3.9%, respectively [12]. These studies showed that EPS is a rare condition; but that it has a high mortality rate. Previous studies have provided insight into the pathophysiology of EPS and identified possible risk factors. Several putative causative factors for the development of EPS were reported in epidemiologic or animal studies, including peritonitis caused by bacterial or fungal organisms and exposure to plasticizers, acidic pH, and glucose degradation products in PD solutions [30].

In PD patients with peritonitis, an inflammatory process occurs, but the roles of T cells and the patterns of cytokine secretion also have not yet been clarified. CD4⁺ T helper (Th) cells are a subcategory of T lymphocytes that play a central role in modulating immune responses. Three major subtypes of effector T helper cells have been identified, Th1, Th2, and Th17 cells [8, 25, 29]. Th1 cells induce cellular immunity and granuloma formation and protect against intracellular pathogens [16, 31]. The Th2 subset favors production of the various immunoglobulin classes that shape or help humoral immunity [16]. Th17 cells participate in the development of autoimmunity; and play an important role in host defense against infection [36]. These three polarized T helper subsets can be identified by the cytokines they secrete. Th1 cells produce interleukin (IL)-2 and interferon- γ (IFN- γ), Th2 cells produce IL-4, IL-5, and IL-13; and Th17 cells produce IL-17, IL-21, and IL-22 [24]. Klínger *et al.* reported that patients on PD with or without peritonitis showed immune activation *per se* and high production of pro-inflammatory cytokines accompanied by a strong pattern of Th2 cytokines and a deficiency of IFN- γ production. This indicated immunodeviation towards a Th2 response and Th1 immunodeficiency [16].

Experimental models of EPS have been described, and several agents have been used to induce EPS, including chlorhexidine gluconate (CG) [34], acidic glucose solution (pH 3.8) [26], and acidic glucose solution (pH 5.0) supplemented with methylglyoxal [9, 30]. CG, a chemical irritant, is the most commonly used agent, and repeated injections of CG in rats or mice disrupt mesothelial cell integrity and cause subsequent injury in subserosal tissue, leading to inflammatory responses and subsequent excessive fibrosis. The progression and mac-

roscopic and histological findings induced by CG are similar to EPS in human patients [30].

T-bet, GATA-3, and retinoic acid-related orphan receptor gamma-t (ROR γ t) are Th1 [35], Th2 [46, 47], and Th17 lineage commitment transcription factors [11, 40], respectively. We previously generated Th1-biased (T-bet transgenic (Tg)) mice [10], Th2-biased (GATA-3 Tg) mice [44], and Th17-biased (ROR γ t Tg) mice [43] to clarify relationships in several diseases using Th1, Th2, and Th17 mouse backgrounds [1, 10, 14, 15, 17, 23, 32, 43, 44]. In this study, we used Th1, Th2, and Th17-biased mice to elucidate the roles of T helper cells in a CG-induced peritoneum fibrosis (PF) model.

Materials and Methods

Animals

T-bet Tg, GATA-3, and ROR γ t Tg male mice on the C57BL/6J background and their wild-type littermates were used. Transgenic mice overexpressing T-bet, GATA-3, or ROR γ t under the control of the CD2 promoter were generated in our laboratory, as previously described [10, 43, 44]. Mice were fed a normal diet comprised of commercial laboratory chow (MF, Oriental Yeast Co., Ltd., Tokyo, Japan) and were maintained under specific pathogen-free conditions in the Laboratory Animal Resource Center of the University of Tsukuba. All experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals at the University of Tsukuba, and the study was approved by the Institutional Review Board of the university.

Mice PF model

Ten-week-old mice were administered 0.1% CG (0.01 ml/g body weight) in 15% ethanol intraperitoneally three times a week. Control mice were injected with 15% ethanol in 2 ml of saline intraperitoneally. After 21 days, mice were sacrificed, and peritoneal tissues were obtained for the study.

Intraperitoneal administration of IFN- γ and anti-IL-13 antibody

Mice were administered IFN- γ (R&D Systems, Minneapolis, MN, USA) (100 unit/g body weight), goat anti-mouse IL-13 antibody (R&D) (1 μ g/g body weight), and normal goat IgG control (R&D) (1 μ g/g body weight) intraperitoneally two times a week. IFN- γ , anti-IL-13 antibody, and normal IgG control injection started one

week prior to CG administration. The period of IFN- γ , anti-IL-13 antibody, and normal IgG control injection was four weeks. Mice were also administered 0.1% CG (0.01 ml/g body weight) in 15% ethanol intraperitoneally three times a week for three weeks.

Histopathological analysis and immunohistochemistry

Organs were fixed with 10% formalin in 0.01 M phosphate buffer (pH 7.2) and embedded in paraffin. Sections (3 μ m) were stained with hematoxylin and eosin (H&E) for histopathological examination by light microscopy. We used a monoclonal anti- α smooth muscle actin antibody (α -SMA) (Sigma, St Louis, MO, USA), a rat anti-mouse macrophage (F4/80) antibody (Cedarlane Labs, Burlington, ON, Canada), and a rabbit anti-collagen III antibody (LSL Co., Ltd., Tokyo, Japan). Staining for α -SMA was performed using Histofine Simple Stain Max PO (mouse) (Nichirei, Tokyo, Japan). Anti-collagen III and F4/80 staining were performed using and Histofine Simple Stain Max PO (rat) (Nichirei).

Morphometric analysis of histology and immunohistology

Morphometric analyses were performed using a BIO-REVO BZ-9000 fluorescence microscope (Keyence, Osaka, Japan). Fibrotic change was evaluated by measuring the full thickness of the submesothelium in Masson's trichrome-stained sections oriented perpendicular from the top of the muscle layer to the serosal surface in 3 randomly selected fields. The stained area of α -SMA and collagen III was assessed in a predetermined field (magnification $\times 40$) of the submesothelial zone in 3 randomly selected fields. The number of cells positive for F4/80 (magnification $\times 100$) in the submesothelial zone was counted in 3 randomly selected fields.

Peritoneal lavage fluid

The peritoneal cavity was lavaged with 4 ml of sterile saline, and this peritoneal lavage fluid was collected. The peritoneal lavage fluid was then stored at -20°C for assessment of cytokine levels.

Measurement of cytokines

Appropriate ELISA kits were used to determine the levels of IFN- γ , IL-4, IL-5, and IL-13 (R&D Systems), in accordance with the manufacturer's instructions.

Statistical analysis

All data are expressed as means \pm SEM. Multiple data




Fig. 1. Body weight changes of control mice and chlorhexidine gluconate (CG)-injected mice. The ratios of body weight change between the weights on day 21 and before treatments are shown. W, wild-type mice; T, T-bet transgenic (Tg) mice; G, GATA-3 Tg mice; R, ROR γ t Tg mice. Data represent means \pm SEM. * $P < 0.01$, CG-injected GATA-3 Tg mice vs. control GATA-3 Tg mice, CG-injected wild-type mice, and T-bet Tg and ROR γ t Tg mice.

comparisons were performed by one-way analysis of variance (ANOVA). P values < 0.05 were considered statistically significant.

Results

GATA-3 Tg mice developed significant body weight loss caused by CG administration

We injected CG into wild-type, T-bet Tg, GATA-3 Tg, and ROR γ t Tg mice and analyzed body weight on day 21. Body weight ratio was calculated by comparing the posttreatment body weight with the pretreatment body weight (Fig. 1). There were no significant changes in the control groups. In the CG treatment groups, the body weight ratio in GATA-3 Tg mice (0.93 ± 0.02) was significantly decreased compared with wild-type (1.01 ± 0.02), T-bet Tg (0.99 ± 0.02), and ROR γ t Tg mice (1.00 ± 0.01). The body weight ratio in CG-treated GATA-3 Tg mice was also significantly decreased compared with control GATA-3 Tg mice (1.05 ± 0.02).

CG-injected GATA-3 Tg mice developed a distended intestinal tract and surface bleeding

Mice were sacrificed on day 21. All mice developed peritonitis. However, CG-injected GATA-3 Tg mice developed the most severe peritonitis compared with the



Fig. 2. Macroscopic findings of the peritoneum of CG-injected mice. CG-injected mice were sacrificed on day 21 and observed macroscopically. Representative mice are shown. CG-injected GATA-3 Tg mice developed severe distended intestinal tract and surface bleeding. The gastrointestinal loop in the CG-injected GATA-3 Tg mouse shows adhesion and bleeding.

other mice (Fig. 2). Distended intestinal tract and predominant bleeding on the surface of the intestinal tract were only detected in CG-injected GATA-3 Tg mice.

CG-injected GATA-3 Tg mice developed a thickened peritoneum

Masson's trichrome staining was used to analyze peritoneal thickness (Fig. 3). In the control groups, the peritoneal tissue consisted of a peritoneal mesothelial monolayer (Fig. 3A). Compared with the control group, peritoneal tissue of the GC-injected groups showed significant thickening of the submesothelial compact zone (Fig. 3B and C). The mean peritoneal thicknesses of the control wild-type, T-bet Tg, GATA-3 Tg, and RORγt Tg mice were $24.3 \pm 2.4 \mu\text{m}$, $25.4 \pm 3.9 \mu\text{m}$, $25.0 \pm 2.0 \mu\text{m}$, and $25.3 \pm 1.4 \mu\text{m}$, respectively. The mean peritoneal thicknesses of the CG-injected wild-type, T-bet Tg, GATA-3 Tg, and RORγt Tg mice were $114.5 \pm 9.0 \mu\text{m}$, $76.3 \pm 16.9 \mu\text{m}$, $145.3 \pm 16.5 \mu\text{m}$, and $104.2 \pm 11.5 \mu\text{m}$, respectively. The thickness of the submesothelial compact zone in CG-injected GATA-3 Tg mice was significantly greater than in the other CG-injected groups.

Increased expression of α -SMA in the submesothelial zone of CG-injected GATA-3 Tg mice

The expression of α -SMA was rarely observed in the submesothelial zone in control mice (Supplementary Fig. 1A). The mean areas of positive α -SMA staining of the control wild-type, T-bet Tg, GATA-3 Tg, and RORγt Tg mice were $13.7 \pm 2.5 \times 10^3 \mu\text{m}^2$, $12.0 \pm 1.0 \times 10^3 \mu\text{m}^2$, $15.9 \pm 4.0 \times 10^3 \mu\text{m}^2$, and $16.0 \pm 2.8 \times 10^3 \mu\text{m}^2$, respectively (Supplementary Fig. 1B). The mean areas of positive α -SMA staining of the CG-injected wild-type,

T-bet Tg, GATA-3 Tg, and RORγt Tg mice were $77.7 \pm 5.2 \times 10^3 \mu\text{m}^2$, $51.4 \pm 8.6 \times 10^3 \mu\text{m}^2$, $124.3 \pm 29.2 \times 10^3 \mu\text{m}^2$, and $71.2 \pm 19.7 \times 10^3 \mu\text{m}^2$, respectively (Fig. 4A and Supplementary Fig. 1B). In the CG-injected group, increased expression of α -SMA was observed, and the positive areas in CG-injected GATA-3 Tg mice were significantly larger than those in the other CG-injected groups.

Increased expression of collagen III in the submesothelial zone of CG-injected GATA-3 Tg mice

In the control groups, the expression of collagen III was minimal in the submesothelial zone (Supplementary Fig. 2A). The mean areas of positive collagen III staining of the control wild-type, T-bet Tg, GATA-3 Tg, and RORγt Tg mice were $22.7 \pm 2.6 \times 10^3 \mu\text{m}^2$, $23.6 \pm 5.8 \times 10^3 \mu\text{m}^2$, $21.3 \pm 2.9 \times 10^3 \mu\text{m}^2$, and $21.7 \pm 3.3 \times 10^3 \mu\text{m}^2$, respectively (Supplementary Fig. 2B). The mean areas of positive collagen III staining of the CG-injected wild-type, T-bet Tg, GATA-3 Tg, and RORγt Tg mice were $106.7 \pm 26.5 \times 10^3 \mu\text{m}^2$, $47.1 \pm 12.9 \times 10^3 \mu\text{m}^2$, $117.8 \pm 14.3 \times 10^3 \mu\text{m}^2$, and $62.0 \pm 16.4 \times 10^3 \mu\text{m}^2$, respectively (Fig. 4B and Supplementary Fig. 2B). In the CG-injected group, increased expression of collagen III was observed, and the positive areas in CG-injected GATA-3 Tg mice were significantly larger than in the other CG-injected groups.

Increased numbers of F4/80-positive macrophage cells in the submesothelial zone were observed in CG-injected GATA-3 Tg mice

We examined expression of the mouse monocyte/macrophage surface marker F4/80 in the peritoneum (Supplementary Fig. 3A). The mean numbers of F4/80-




Fig. 3. Representative light microscopic features of peritoneal tissue on days 21 in control mice (A) and CG-injected wild-type (W), T-bet Tg (T), GATA-3 Tg (G), and RORγt Tg (R) mice (B) (Masson-trichrome stain, original magnification $\times 100$, scale bar 100 μm). Bars indicate thickness of the submesothelium. (C) Bar graph showing the thickness of the submesothelial zone. Data represent means \pm SEM. * $P < 0.01$ vs. CG-injected T-bet Tg and RORγt Tg mice; ** $P < 0.05$ vs. CG-injected wild-type mice; *** $P < 0.05$ vs. CG-injected T-bet Tg mice.

positive cells in control wild-type, T-bet Tg, GATA-3 Tg, and RORγt Tg mice were 3.0 ± 1.1 , 1.7 ± 1.7 , 3.0 ± 2.0 , and 1.7 ± 1.7 in the observation field, respectively (Supplementary Fig. 3B). The mean numbers of F4/80-positive cells in CG-injected wild-type, T-bet Tg, GATA-3 Tg, and RORγt Tg mice were 19.0 ± 3.9 , 7.0 ± 3.0 , 44.3 ± 12.1 , and 9.7 ± 1.9 in the observation field, respectively (Fig. 4C and Supplementary Fig. 3B). There were no significant differences between the control groups. In the CG-injected groups, the number of F4/80-positive cells was significantly increased in the CG-injected GATA-3 Tg mice compared with the other CG-injected groups.

Increased IFN- γ level in peritoneal fluid of CG-injected T-bet Tg mice and increased IL-13 level in CG-injected GATA-3 Tg mice

CG-injected GATA-3 Tg mice developed a marked severe PF compared with the other CG-injected groups. Th2 cytokines play important roles in fibrosis [39]. Because CG-injected GATA-3 Tg mice developed severe peritonitis and adhesion on day 21, we could not directly examine the peritoneal fluid. Next we examined the expression of cytokines in the peritoneal fluid on day 8 to analyze the development of PF. In this analysis, we examined the levels of IFN- γ , IL-4, IL-5, and IL-13 (Fig. 5 and Supplementary Fig. 4). There were no significant




Fig. 4. Immunohistochemistry of α -SMA expression (arrow-heads) (A), collagen III expression (B), and F4/80-positive cells (arrowheads) (C) in peritoneal tissue on days 21 in CG-injected wild-type (W), T-bet Tg (T), GATA-3 Tg (G), and ROR γ t Tg (R) mice (original magnification $\times 200$ (A and C), $\times 100$ (B); scale bar 100 μ m).




Fig. 5. Expression of cytokines, IFN- γ (A) and IL-13 (B), in peritoneal fluid of control and CG-injected mice. W, wild-type mice; T, T-bet Tg mice; G, GATA-3 Tg mice; R, ROR γ t Tg mice. Data represent means \pm SEM. * $P < 0.01$ vs. CG-injected wild-type mice, GATA-3 Tg mice, and ROR γ t Tg mice; ** $P < 0.05$ vs. CG-injected T-bet Tg mice and ROR γ t Tg mice; *** $P < 0.01$ vs. CG-injected T-bet Tg mice and ROR γ t Tg mice; $P < 0.05$ vs. CG-injected wild-type mice; $n = 5$ in each group.

differences in the levels of IL-4, and IL-5 between wild-type mice and Tg mice (Supplementary Figs. 4A and B). IL-13 levels in CG-injected GATA-3 Tg mice were significantly higher than in CG-injected wild-type mice (Fig. 5B). The mean IL-13 levels in control wild-type, T-bet Tg, GATA-3 Tg, and ROR γ t Tg mice were 1.3 ± 0.8 pg/ml, 0.7 ± 0.5 pg/ml, 1.0 ± 1.1 pg/ml, and 0.8 ± 0.7 pg/ml, respectively. The mean IL-13 levels in CG-injected wild-type, T-bet Tg, GATA-3 Tg, and ROR γ t Tg mice were 3.6 ± 1.9 pg/ml, 0.0 ± 0.0 pg/ml, 7.0 ± 1.7




Fig. 6. Intraperitoneal administration of IFN- γ in CG-injected wild-type mice. Representative light microscopic features of peritoneal tissue on days 21 in saline-injected, CG with saline-injected, and CG with IFN- γ -injected wild-type mice (A) (Masson-trichrome stain, original magnification $\times 100$, scale bar $100 \mu\text{m}$). Bars indicate thickness of the submesothelium. (B) Bar graph showing the thickness of the submesothelial zone. Data represent means \pm SEM. * $P < 0.01$ vs. saline-injected and CG with IFN- γ injected wild-type mice; ** $P < 0.01$ vs. saline-injected wild-type mice.

pg/ml, and 0.2 ± 0.2 pg/ml, respectively. Furthermore, IFN- γ levels in CG-injected T-bet Tg mice were significantly higher than in the other CG-injected mice (Fig. 5A). The mean IFN- γ levels in control wild-type, T-bet Tg, GATA-3 Tg, and ROR γ t Tg mice were 0.3 ± 0.2 pg/

ml, 2.9 ± 0.5 pg/ml, 0.8 ± 0.5 pg/ml, and 1.2 ± 0.2 pg/ml, respectively. The mean IFN- γ levels in CG-injected wild-type, T-bet Tg, GATA-3 Tg, and ROR γ t Tg mice were 2.4 ± 0.6 pg/ml, 7.7 ± 3.9 pg/ml, 2.6 ± 1.0 pg/ml, and 1.8 ± 0.4 pg/ml, respectively.

Intraperitoneal administration of IFN- γ improved PF

We next assessed the effects of exogenously administered IFN- γ on the development of PF using wild-type mice. Exogenous administration of IFN- γ significantly improved PF (Fig. 6). The mean peritoneal thicknesses of the control (saline only), CG-injected, and CG with IFN- γ administration wild-type mice were $18.9 \pm 1.4 \mu\text{m}$, $126.5 \pm 5.7 \mu\text{m}$, and $74.3 \pm 4.9 \mu\text{m}$, respectively. The thickness of the submesothelial compact zone in mice administered IFN- γ was significantly decreased compared with CG-injected only mice.

Discussion

It is well known that patients with end-stage renal disease present with disturbances of the immune system [5]. Immune system dysfunction in uremia is mainly the result of altered function of various types of immune cells, including polymorphonuclear leukocytes, monocytes, natural killer cells, and T lymphocytes [21, 22]. T cells play an important role in the acquired immune response and a target specific antigen by T cell receptor recognition. The peritoneum is a special environment within which T cells react [7]. Most peritoneal lymphocytes are composed of T cells divided into several subpopulations, including Th cells, cytotoxic T lymphocytes, $\gamma\delta$ T cells, memory T cells, and regulatory T cells. Th cells are one of the most important cell populations in the peritoneum and are composed of three major subpopulations, defined as Th1, Th2, and Th17 [8, 25, 29]. Yokoyama *et al.* also reported that Th cells from PD patients manifest a dysregulated differentiation profile characterized by a marked increase in the percentage of Th2 cell with a normal percentage of Th1 cells [45]. In PD patients with peritonitis, an inflammatory process occurs, but the patterns of Th cells and the cytokine secretion in the inflammatory process have not yet been clarified. Previous reports described that peritonitis in PD patients is predominantly a type 1 immune response characterized by the early induction of TNF- α , IL-1 β , IL-12, and IL-18, followed by elevated levels of IFN- γ [2, 38]. The presence of a Th1 phenotype in peritoneal

effluents seems to lower the risk of peritonitis [4, 20]. These findings suggested that peritoneal Th1 cells may improve cooperation among T cells, peritoneal macrophages, and peritoneal mesothelial cells. In our study; of CG-injected groups, Th1-biased mice showed the most reduced PF. Our results agree with those of previous reports. Th1 cells produce a high amount of IFN- γ , which can increase the killing activity of peritoneal macrophages and the antigen-presenting activity of peritoneal mesothelial cells. A previous study by Wang and Lin described this possibility in PD patients with peritonitis, showing that early high IL-12, IL-18, and IFN- γ levels correlated with rapid response to antibiotic treatment [7, 38].

EPS is characterized by progressive and excessive fibrotic thickening of the peritoneum. Tissue fibrosis in many disorders, such as idiopathic pulmonary fibrosis, hepatic fibrosis, and systemic sclerosis, is a leading cause of mortality [41]. Although the pathogenetic principles of fibrosis are still unknown, the early stages of fibrotic conditions are characterized by immunologic-inflammatory hallmarks [39]. Fibrotic tissue is always infiltrated by immune cells. Th cells and their secreted cytokines play a prominent role in the initiation and progression of fibrosis. Th1 cells are thought to mediate tissue damage and collagen degradation, whereas Th2 cells and their corresponding cytokines are linked with fibrogenesis. Thus, Th1 and Th2 cytokines play opposing roles in fibrosis: the Th2 cytokines IL-4 and IL-13 are strongly pro-fibrotic, whereas the Th1 cytokines IFN- γ and IL-12 suppress the development of tissue fibrosis [42]. In this study, we showed that IFN- γ administration reduced the deterioration of PF in GC-injected wild-type mice. Many reports have linked IL-13 with fibrosis diseases, but whether IL-13 is associated with EPS is unclear. Indeed, IL-13 was found to be directly fibrotic in a hepatic fibrosis model, and deletion of IL-13 was associated with reduced fibrosis and collagen deposition. A study using double IL-4 and IL-13 knockout mice demonstrated IL-13 was the predominant pro-fibrotic mediator in a natural model of hepatic fibrosis [6, 27]. Furthermore, targeted pulmonary overexpression of IL-13 using genetic approaches in mice resulted lung fibrosis [48]. In this study, we showed that Th2-biased mice developed severe PF and that high levels of IL-13 expression were detected in peritoneal fluid. We also administered an anti-IL-13 antibody to GC-injected wild-type mice in our study (Supplementary Fig. 5).

However, we could not clearly show the effect of anti-IL-13 therapy. Further experiments would be required to examine the IL-13 antibody volume and the schedule of administration in the GC-injected model.

IL-17 produced by Th17 also has been implicated in some fibrotic disorders [19, 28, 33]. Wang *et al.* reported that manipulation of IL-17 cytokine expression in patients with peritonitis might modulate peritoneal immune responses and affect peritonitis outcomes [37]. In our study, Th17-biased mice, ROR γ t Tg mice, did not develop a severe form of PF. Transgenic mice overexpressing ROR γ t under the control of the CD2 promoter induced a Th17-biased background that might have affected Th2 cells or the expression of related factors, which might have contributed to the development of PF. Further studies to define the other Th2-related factors may clarify the mechanisms responsible for the development of PF.

In conclusion, we observed that Th2-biased mice developed severe experimental PF but that Th1-biased mice did not. Our results suggest that Th1 and Th2 cells, and their corresponding cytokines may play important roles in the development of experimental PF. In future studies, the regulation of Th cell subsets, such as Th2 background suppression or Th1 background acceleration, might be effective for EPS treatment.

Acknowledgments

This work was supported by JSPS KAKENHI Grant-in-Aid for Scientific Research (C) Number 25461240, Grant-in-Aid for Scientific Research (S) Number 26221004, and Grant-in-Aid for Challenging Exploratory Research Number 26640049.

References

1. Ano, S., Morishima, Y., Ishii, Y., Yoh, K., Yageta, Y., Ohtsuka, S., Matsuyama, M., Kawaguchi, M., Takahashi, S., and Hizawa, N. 2013. Transcription factors GATA-3 and ROR γ t are important for determining the phenotype of allergic airway inflammation in a murine model of asthma. *J. Immunol.* 190: 1056–1065. [Medline] [CrossRef]
2. Brauner, A., Hylander, B., and Wretling, B. 1996. Tumor necrosis factor- α , interleukin-1 β , and interleukin-1 receptor antagonist in dialysate and serum from patients on continuous ambulatory peritoneal dialysis. *Am. J. Kidney Dis.* 27: 402–408. [Medline] [CrossRef]
3. Brown, M.C., Simpson, K., Keressens, J.J., Mactier, R.A., Scottish Renal Registry 2009. Encapsulating peritoneal scle-

- rosis in the new millennium: a national cohort study. *Clin. J. Am. Soc. Nephrol.* 4: 1222–1229. [Medline] [CrossRef]
4. Chiesa, S., Vigo, G., Cappa, F., Prigione, I., Pistoia, V., Verina, E., Perfumo, F., and Barbano, G. 2004. Peritoneal T cell responses can be polarized toward Th1 or Th2 in children on chronic peritoneal dialysis. *Artif. Organs* 28: 750–752. [Medline] [CrossRef]
 5. Eleftheriadis, T., Antoniadi, G., Liakopoulos, V., Kartsios, C., and Stefanidis, I. 2007. Disturbances of acquired immunity in hemodialysis patients. *Semin. Dial.* 20: 440–451. [Medline] [CrossRef]
 6. Fallon, P.G., Richardson, E.J., McKenzie, G.J., and McKenzie, A.N. 2000. Schistosome infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent. *J. Immunol.* 164: 2585–2591. [Medline] [CrossRef]
 7. Glik, A. and Douvdevani, A. 2006. T lymphocytes: the “cellular” arm of acquired immunity in the peritoneum. *Perit. Dial. Int.* 26: 438–448. [Medline]
 8. Harrington, L.E., Hatton, R.D., Mangan, P.R., Turner, H., Murphy, T.L., Murphy, K.M., and Weaver, C.T. 2005. Interleukin 17-producing CD4⁺ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. *Nat. Immunol.* 6: 1123–1132. [Medline] [CrossRef]
 9. Hirahara, I., Kusano, E., Yanagiba, S., Miyata, Y., Ando, Y., Muto, S., and Asano, Y. 2006. Peritoneal injury by methylglyoxal in peritoneal dialysis. *Perit. Dial. Int.* 26: 380–392. [Medline]
 10. Ishizaki, K., Yamada, A., Yoh, K., Nakano, T., Shimohata, H., Maeda, A., Fujioka, Y., Morito, N., Kawachi, Y., Shibuya, K., Otsuka, F., Shibuya, A., and Takahashi, S. 2007. Th1 and type 1 cytotoxic T cells dominate responses in T-bet overexpression transgenic mice that develop contact dermatitis. *J. Immunol.* 178: 605–612. [Medline] [CrossRef]
 11. Ivanov, I.I., McKenzie, B.S., Zhou, L., Tadokoro, C.E., Lepelletier, A., Lafaille, J.J., Cua, D.J., and Littman, D.R. 2006. The orphan nuclear receptor ROR γ directs the differentiation program of proinflammatory IL-17⁺ T helper cells. *Cell* 126: 1121–1133. [Medline] [CrossRef]
 12. Johnson, D.W., Cho, Y., Livingston, B.E., Hawley, C.M., McDonald, S.P., Brown, F.G., Rosman, J.B., Bannister, K.M., and Wiggins, K.J. 2010. Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes. *Kidney Int.* 77: 904–912. [Medline] [CrossRef]
 13. Kawanishi, H., Kawaguchi, Y., Fukui, H., Hara, S., Imada, A., Kubo, H., Kin, M., Nakamoto, M., Ohira, S., and Shoji, T. 2004. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. *Am. J. Kidney Dis.* 44: 729–737. [Medline] [CrossRef]
 14. Kimura, T., Ishii, Y., Yoh, K., Morishima, Y., Iizuka, T., Kiwamoto, T., Matsuno, Y., Homma, S., Nomura, A., Sakamoto, T., Takahashi, S., and Sekizawa, K. 2006. Overexpression of the transcription factor GATA-3 enhances the development of pulmonary fibrosis. *Am. J. Pathol.* 169: 96–104. [Medline] [CrossRef]
 15. Kiwamoto, T., Ishii, Y., Morishima, Y., Yoh, K., Maeda, A., Ishizaki, K., Iizuka, T., Hegab, A.E., Matsuno, Y., Homma, S., Nomura, A., Sakamoto, T., Takahashi, S., and Sekizawa, K. 2006. Transcription factors T-bet and GATA-3 regulate development of airway remodeling. *Am. J. Respir. Crit. Care Med.* 174: 142–151. [Medline] [CrossRef]
 16. Klinger, J., Enríquez, J., Arturo, J.A., Delgado, M., Avila, G., and Ceballos, O. 2002. Cytokines and peritonitis in continuous ambulatory peritoneal dialysis: immunodeviation and immunodeficiency. *Adv. Perit. Dial.* 18: 170–176. [Medline]
 17. Kondo, Y., Iizuka, M., Wakamatsu, E., Yao, Z., Tahara, M., Tsuboi, H., Sugihara, M., Hayashi, T., Yoh, K., Takahashi, S., Matsumoto, I., and Sumida, T. 2012. Overexpression of T-bet gene regulates murine autoimmune arthritis. *Arthritis Rheum.* 64: 162–172. [Medline] [CrossRef]
 18. Korte, M.R., Sampimon, D.E., Betjes, M.G., and Krediet, R.T. 2011. Encapsulating peritoneal sclerosis: the state of affairs. *Nat. Rev. Nephrol.* 7: 528–538. [Medline]
 19. Lafdil, F., Miller, A.M., Ki, S.H., and Gao, B. 2010. Th17 cells and their associated cytokines in liver diseases. *Cell. Mol. Immunol.* 7: 250–254. [Medline] [CrossRef]
 20. Lamperi, S. and Carozzi, S. 1988. Interferon-gamma (IFN-gamma) as in vitro enhancing factor of peritoneal macrophage defective bactericidal activity during continuous ambulatory peritoneal dialysis (CAPD). *Am. J. Kidney Dis.* 11: 225–230. [Medline] [CrossRef]
 21. Libetta, C., Esposito, P., Sepe, V., Guastoni, C., Zucchi, M., Meloni, F., and Dal Canton, A. 2011. Effects of different peritoneal dialysis fluids on the TH1/TH2 balance. *Eur. Cytokine Netw.* 22: 24–31. [Medline]
 22. Lim, W.H., Kireta, S., Leedham, E., Russ, G.R., and Coates, P.T. 2007. Uremia impairs monocyte and monocyte-derived dendritic cell function in hemodialysis patients. *Kidney Int.* 72: 1138–1148. [Medline] [CrossRef]
 23. Matsuno, Y., Ishii, Y., Yoh, K., Morishima, Y., Haraguchi, N., Kikuchi, N., Iizuka, T., Kiwamoto, T., Homma, S., Nomura, A., Sakamoto, T., Ohtsuka, M., Hizawa, N., and Takahashi, S. 2007. Overexpression of GATA-3 protects against the development of hypersensitivity pneumonitis. *Am. J. Respir. Crit. Care Med.* 176: 1015–1025. [Medline] [CrossRef]
 24. Miossec, P., Korn, T., and Kuchroo, V.K. 2009. Interleukin-17 and type 17 helper T cells. *N. Engl. J. Med.* 361: 888–898. [Medline] [CrossRef]
 25. Mosmann, T.R., Cherwinski, H., Bond, M.W., Giedlin, M.A., and Coffman, R.L. 1986. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. *J. Immunol.* 136: 2348–2357. [Medline]
 26. Nakamoto, H., Imai, H., Ishida, Y., Yamanouchi, Y., Inoue, T., Okada, H., and Suzuki, H. 2001. New animal models for encapsulating peritoneal sclerosis—role of acidic solution. *Perit. Dial. Int.* 21: S349–S353. [Medline]
 27. O'Reilly, S., Hügler, T., and van Laar, J.M. 2012. T cells in systemic sclerosis: a reappraisal. *Rheumatology (Oxford)* 51: 1540–1549. [Medline] [CrossRef]
 28. Okamoto, Y., Hasegawa, M., Matsushita, T., Hamaguchi, Y., Huu, D.L., Iwakura, Y., Fujimoto, M., and Takehara, K. 2012. Potential roles of interleukin-17A in the development of skin fibrosis in mice. *Arthritis Rheum.* 64: 3726–3735. [Medline] [CrossRef]
 29. Park, H., Li, Z., Yang, X.O., Chang, S.H., Nurieva, R., Wang,

- Y.H., Wang, Y., Hood, L., Zhu, Z., Tian, Q., and Dong, C. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. *Nat. Immunol.* 6: 1133–1141. [[Medline](#)] [[CrossRef](#)]
30. Park, S.H., Kim, Y.L., and Lindholm, B. 2008. Experimental encapsulating peritoneal sclerosis models: pathogenesis and treatment. *Perit. Dial. Int.* 28: S21–S28. [[Medline](#)]
31. Romagnani, S. 1994. Lymphokine production by human T cells in disease states. *Annu. Rev. Immunol.* 12: 227–257. [[Medline](#)] [[CrossRef](#)]
32. Shimohata, H., Yamada, A., Yoh, K., Ishizaki, K., Morito, N., Yamagata, K., and Takahashi, S. 2009. Overexpression of T-bet in T cells accelerates autoimmune glomerulonephritis in mice with a dominant Th1 background. *J. Nephrol.* 22: 123–129. [[Medline](#)]
33. Simonian, P.L., Roark, C.L., Wehrmann, F., Lanham, A.K., Diaz del Valle, F., Born, W.K., O'Brien, R.L., and Fontenot, A.P. 2009. Th17-polarized immune response in a murine model of hypersensitivity pneumonitis and lung fibrosis. *J. Immunol.* 182: 657–665. [[Medline](#)] [[CrossRef](#)]
34. Suga, H., Teraoka, S., Ota, K., Komemushi, S., Furutani, S., Yamauchi, S., and Margolin, S. 1995. Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats. *Exp. Toxicol. Pathol.* 47: 287–291. [[Medline](#)] [[CrossRef](#)]
35. Szabo, S.J., Kim, S.T., Costa, G.L., Zhang, X., Fathman, C.G., and Glimcher, L.H. 2000. A novel transcription factor, T-bet, directs Th1 lineage commitment. *Cell* 100: 655–669. [[Medline](#)] [[CrossRef](#)]
36. Tesmer, L.A., Lundy, S.K., Sarkar, S., and Fox, D.A. 2008. Th17 cells in human disease. *Immunol. Rev.* 223: 87–113. [[Medline](#)] [[CrossRef](#)]
37. Wang, H.H., Lee, T.Y., and Lin, C.Y. 2011. Kinetics and involvement of interleukin-17 in the outcome of peritonitis in nondiabetic patients undergoing peritoneal dialysis. *J. Chin. Med. Assoc.* 74: 11–15. [[Medline](#)] [[CrossRef](#)]
38. Wang, H.H. and Lin, C.Y. 2005. Interleukin-12 and -18 levels in peritoneal dialysate effluent correlate with the outcome of peritonitis in patients undergoing peritoneal dialysis: implications for the Type I/Type II T-cell immune response. *Am. J. Kidney Dis.* 46: 328–338. [[Medline](#)] [[CrossRef](#)]
39. Wick, G., Backovic, A., Rabensteiner, E., Plank, N., Schwentner, C., and Sgonc, R. 2010. The immunology of fibrosis: innate and adaptive responses. *Trends Immunol.* 31: 110–119. [[Medline](#)] [[CrossRef](#)]
40. Wilson, N.J., Boniface, K., Chan, J.R., McKenzie, B.S., Blumenschein, W.M., Mattson, J.D., Basham, B., Smith, K., Chen, T., Morel, F., Lecron, J.C., Kastelein, R.A., Cua, D.J., McClanahan, T.K., Bowman, E.P., and de Waal Malefyt, R. 2007. Development, cytokine profile and function of human interleukin 17-producing helper T cells. *Nat. Immunol.* 8: 950–957. [[Medline](#)] [[CrossRef](#)]
41. Wynn, T.A. 2004. Fibrotic disease and the T(H)1/T(H)2 paradigm. *Nat. Rev. Immunol.* 4: 583–594. [[Medline](#)] [[CrossRef](#)]
42. Wynn, T.A. 2008. Cellular and molecular mechanisms of fibrosis. *J. Pathol.* 214: 199–210. [[Medline](#)] [[CrossRef](#)]
43. Yoh, K., Morito, N., Ojima, M., Shibuya, K., Yamashita, Y., Morishima, Y., Ishii, Y., Kusakabe, M., Nishikii, H., Fujita, A., Matsunaga, E., Okamura, M., Hamada, M., Suto, A., Nakajima, H., Shibuya, A., Yamagata, K., and Takahashi, S. 2012. Overexpression of ROR γ t under control of the CD2 promoter induces polyclonal plasmacytosis and autoantibody production in transgenic mice. *Eur. J. Immunol.* 42: 1999–2009. [[Medline](#)] [[CrossRef](#)]
44. Yoh, K., Shibuya, K., Morito, N., Nakano, T., Ishizaki, K., Shimohata, H., Nose, M., Izui, S., Shibuya, A., Koyama, A., Engel, J.D., Yamamoto, M., and Takahashi, S. 2003. Transgenic overexpression of GATA-3 in T lymphocytes improves autoimmune glomerulonephritis in mice with a BXSB/MpJ-Yaa genetic background. *J. Am. Soc. Nephrol.* 14: 2494–2502. [[Medline](#)] [[CrossRef](#)]
45. Yokoyama, T., Nitta, K., Futatsuyama, K., Hayashi, T., Honda, K., Uchida, K., Kawashima, A., Yumura, W., and Nihei, H. 2001. Identification of T helper cell subsets in continuous ambulatory peritoneal dialysis patients. *Nephron* 89: 215–218. [[Medline](#)] [[CrossRef](#)]
46. Zhang, D.H., Cohn, L., Ray, P., Bottomly, K., and Ray, A. 1997. Transcription factor GATA-3 is differentially expressed in murine Th1 and Th2 cells and controls Th2-specific expression of the interleukin-5 gene. *J. Biol. Chem.* 272: 21597–21603. [[Medline](#)] [[CrossRef](#)]
47. Zheng, W. and Flavell, R.A. 1997. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. *Cell* 89: 587–596. [[Medline](#)] [[CrossRef](#)]
48. Zhu, Z., Homer, R.J., Wang, Z., Chen, Q., Geba, G.P., Wang, J., Zhang, Y., and Elias, J.A. 1999. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. *J. Clin. Invest.* 103: 779–788. [[Medline](#)] [[CrossRef](#)]